Clinical trials for Head and neck cancer

84 currently recruiting clinical trials
Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors #NCT05118789
Locally Advanced Metastatic ROS-1 1
4 recruiting sites
Nuvalent Inc.
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT04657068 #2024-511534-12-00
Parties A1, A2, A3 (escalade de dose)
Locally Advanced Metastatic Metastatic Castration-resistant ATM 1 2 3 or more
Systemic Treatment-Naive
5 recruiting sites
Artios Pharma Ltd
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT04657068 #2024-511534-12-00
Dose d'expansion Partie B4
Locally Advanced Metastatic Metastatic Castration-resistant ATM 1 2 3 or more
Systemic Treatment-Naive
5 recruiting sites
Artios Pharma Ltd
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT04657068 #2024-511534-12-00
Dose d'expansion Partie B1
Locally Advanced Metastatic Metastatic Castration-resistant ATM 1 2 3 or more
Systemic Treatment-Naive
5 recruiting sites
Artios Pharma Ltd
Phase 1 / Phase 2 Lung cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Head and neck cancer #NCT06923761 #2023-504845-30-00
Module 2 Cohorte 3 Tumeurs solides avec un TMB médian modéré à élevé
NSCLC (Non-Small Cell Lung Cancer) Stomach Oesogastric junction Esophagus Invasive bladder cancer Oral cavity Nasopharynx Oropharynx Hypopharynx Larynx Nasal cavities and sinuses Adenocarcinoma Squamous cell carcinoma Urothelial carcinoma Locally Advanced Metastatic 1 2 Immunotherapy
Systemic Treatment-Naive
7 recruiting sites
Grey Wolf Therapeutics
Phase 1 / Phase 2 Lung cancer Prostate cancer Colon cancer Rectal cancer Liver and bile duct cancer Head and neck cancer #NCT06725758 #2022-503061-29-00
NSCLC (Non-Small Cell Lung Cancer) Mesothelium Oral cavity Nasopharynx Oropharynx Hypopharynx Larynx Salivary glands Nasal cavities and sinuses Hepatocellular carcinoma Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma Squamous cell carcinoma Locally Advanced Metastatic Metastatic Castration-resistant 1 2 3 or more
Systemic Treatment-Naive
3 recruiting sites
Orion Pharma
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Acute leukemia Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer #NCT07403721
Locally Advanced Metastatic Metastatic Castration-resistant MSI/dMMR 1 2 3 or more
Systemic Treatment-Naive
1 recruiting site
Amgen
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) Small intestine and appendix cancer Thyroid and adrenal gland cancer #NCT05856981 #2022-502757-34-00
Escalade de dose
Locally Advanced Metastatic 1 2 3 or more
Systemic Treatment-Naive
2 recruiting sites
Sairopa BV
Phase 1 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT04777994
Dose d'expansion cohorte combinaison avec inhibiteur PD-1 tumeurs MSI-H
Locally Advanced Metastatic MSI/dMMR 1 2 3 or more Immunotherapy
Systemic Treatment-Naive
4 recruiting sites
Calico Life Sciences LLC
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT04777994
Escalade de dose (Tumeurs solides)
Locally Advanced Metastatic 1 2 3 or more
Systemic Treatment-Naive
4 recruiting sites
Calico Life Sciences LLC